⚲
|
Inotek Pharmaceuticals Corp | |
---|---|
Ticker | RCKT |
CIK # | 0001281895 |
CUSIP | 77313F106 |
Sector | Life Sciences |
Industry | Pharmaceutical Preparations |
Phone | 7816762100 |
Address | 131 Hartwell Ave 1St Floor, Suite 105 Lexington, MA 02421 |
Source | [EDGAR] |
Market Cap, 13F ($) |
---|
Business |
---|
We are a clinical-stage, multi-platform biotechnology company focused on the development of first, only and best-in-class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating pediatric diseases. We currently have three clinical-stage ex vivo lentiviral vector ("LVV") programs currently enrolling patients in the US and EU for Fanconi Anemia ("FA"), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I ("LAD-I"), a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency ("PKD"), a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. Of these, both the Phase 2 FA program and the Phase 1/2 LAD-I program are in registration-enabling studies in the US and EU. In addition, in the US we have a clinical stage in vivo adeno-associated virus ("AAV") program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. Finally, we have a pre-clinical stage LVV program for Infantile Malignant Osteopetrosis ("IMO"), a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption - this program is anticipated to enter the clinic in 2020. We have global commercialization and development rights to all of these product candidates under royalty-bearing license agreements. Additional work in the discovery stage for an FA CRISPR/CAS9 program as well as a gene therapy program for the less common FA subtypes C and G is ongoing. Through our gene therapy platforms, we aim to restore normal cellular function by modifying the defective genes that cause each of the targeted disorders. Genes are composed of sequences of deoxyribonucleic acid ("DNA"), which code for proteins that perform a broad range of physiologic functions in all living organisms. Although genes are passed on from generation to generation, genetic changes, also known as mutations, can occur in this process. These changes can result in the lack of production of proteins or the production of altered proteins with reduced or abnormal function, which can in turn result in disease. |
CIK | Filing | 2011 - 2023 |
---|---|---|
[0001281895] | 10-K | |
[0001281895] | 10-Q | |
[0001281895] | 3 | |
[0001281895] | 4 | |
[0001281895] | 5 | |
[0001281895] | 8-K | |
[0001281895] | SC 13D | |
[0001281895] | SC 13G |